Page 53 - Read Online

Iruzubieta et al. Metab Target Organ Damage. 2025;5:10 https://dx.doi.org/10.20517/mtod.2024.143 Page 15 of 16

presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918-30. DOI PubMed
31. Bataller R, Arab JP, Shah VH. Alcohol-associated hepatitis. N Engl J Med. 2022;387:2436-48. DOI PubMed
32. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in
individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81:930-40. DOI PubMed
33. Whitfield JB, Schwantes-An TH, Darlay R, et al; GenomALC Consortium. A genetic risk score and diabetes predict development of
alcohol-related cirrhosis in drinkers. J Hepatol. 2022;76:275-82. DOI PubMed PMC
34. Burton R, Fryers PT, Sharpe C, et al. The independent and joint risks of alcohol consumption, smoking, and excess weight on
morbidity and mortality: a systematic review and meta-analysis exploring synergistic associations. Public Health. 2024;226:39-52.
DOI PubMed
35. Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clin Med. 2018;18:s54-9. DOI PubMed
PMC
36. Nasr P, Wester A, Ekstedt M, et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-
associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol. 2024;22:1048-57.e2. DOI
PubMed
37. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut.
2024;73:691-702. DOI PubMed
38. Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular
complications. Hepatol Int. 2023;17:350-6. DOI PubMed
39. Santos-Laso A, Gutiérrez-Larrañaga M, Alonso-Peña M, et al. Pathophysiological mechanisms in non-alcoholic fatty liver disease:
from drivers to targets. Biomedicines. 2021;10:46. DOI PubMed PMC
40. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28:179-85. DOI PubMed
41. De Filippo O, Di Pietro G, Nebiolo M, et al. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated
steatotic liver disease patients: a meta-analysis. Eur J Clin Invest. 2024;54:e14188. DOI PubMed
42. Solomon A, Negrea MO, Cipăian CR, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center
cross-sectional study. Healthcare. 2023;11:2696. DOI PubMed PMC
43. Kang MK, Song JE, Loomba R, et al. Comparative associations of MASLD and MAFLD with the presence and severity of coronary
artery calcification. Sci Rep. 2024;14:22917. DOI PubMed PMC
44. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int.
2024;44:1567-74. DOI PubMed
45. Ciardullo S. The MAFLD-MASLD debate: does cardiovascular risk prediction define the winner? Liver Int. 2024;44:1564-6. DOI
PubMed
46. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a
meta-analysis of preliminary evidence. Liver Int. 2024;44:1762-7. DOI PubMed
47. Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-
associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59:150-6. DOI PubMed PMC
48. Chrysavgis L, Cholongitas E. From NAFLD to MASLD: what does it mean? Expert Rev Gastroenterol Hepatol. 2024;18:217-21.
DOI PubMed
49. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026-39.
DOI PubMed
50. Wong VWS, Zelber-Sagi S, Cusi K, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42:2377-89. DOI
PubMed
51. Eskridge W, Cryer DR, Schattenberg JM, et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-
associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023;12:6216. DOI PubMed PMC
52. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver
disease in primary care settings. Hepatology. 2024;79:1393-400. DOI PubMed
53. Iruzubieta P, Santos-Laso A, Arias-Loste MT, Calleja JL, Crespo J. Evaluation of metabolic dysfunction-associated steatotic liver
disease (MASLD) terminology in different clinical settings. J Hepatol. 2024;80:e121-3. DOI PubMed
54. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol.
2024;80:e54-6. DOI PubMed
55. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European
Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic
dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542. DOI PubMed PMC
56. Lazarus JV, Mark HE, Allen AM, et al; Healthy Livers, Healthy Lives Collaborators. A global action agenda for turning the tide on
fatty liver disease. Hepatology. 2024;79:502-23. DOI PubMed PMC
57. Hagström H, Adams LA, Allen AM, et al. The future of international classification of diseases coding in steatotic liver disease: an
expert panel Delphi consensus statement. Hepatol Commun. 2024;8:e0386. DOI PubMed PMC
58. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert
panel on alcohol-related liver disease. J Hepatol. 2024;Epub ahead of print. DOI
59. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new